Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Surv Ophthalmol. 2017 Dec 27;63(4):453–479. doi: 10.1016/j.survophthal.2017.12.008

Figure 22. Administration of exogenous endostatin promoted corneal allograft survival. (.

Figure 22

A) Mice with corneal transplants were treated with subconjunctival injections of either endostatin or PBS (control) from postoperative day (POD) 0 to POD30. In the PBS-treated group, the allografts started to be rejected at POD27. By POD40, 6 of 10 allografts in the PBS group had been rejected. In contrast, all allografts in the endostatin-treated group survived through POD40 (p < 0.01, n = 10). (B) All syngeneic grafts survived in both treatment groups. (C) Exogenous endostatin or PBS was administered to mice from POD20, when the allografts were vascularized, to POD50. By POD60, 75% of the allografts had been rejected, and there was no significant difference between the PBS-treated group and the endostatin-treated group (p > 0.05).182 (Adapted from Tan et al with permission)